Total Payments
$38,054
2022 Payments
$5,154
Companies
2
Transactions
18
Payment Breakdown by Category
Research$37,993 (99.8%)
Food & Beverage$60.61 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $37,993 | 17 | 99.8% |
| Food and Beverage | $60.61 | 1 | 0.2% |
Payments by Type
Research
$37,993
17 transactions
General
$60.61
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $37,993 | 17 | $0 (2022) |
| ABIOMED | $60.61 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $5,154 | 2 | F. Hoffmann-La Roche AG ($5,154) |
| 2021 | $9,091 | 6 | F. Hoffmann-La Roche AG ($9,030) |
| 2020 | $23,809 | 10 | F. Hoffmann-La Roche AG ($23,809) |
All Payment Transactions
18 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/30/2022 | F. Hoffmann-La Roche AG | HEMLIBRA (Biological) | — | In-kind items and services | $3,894.77 | Research |
| Study: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS • Category: Hematology | ||||||
| 09/30/2022 | F. Hoffmann-La Roche AG | HEMLIBRA (Biological) | — | In-kind items and services | $1,259.23 | Research |
| Study: A MULTICENTER, NON-INTERVENTIONAL STUDY EVALUATING BLEEDING INCIDENCE, HEALTH-RELATED QUALITY OF LIFE, AND SAFETY IN PATIENTS WITH HEMOPHILIA A UNDER STANDARD-OF-CARE TREATMENT • Category: Hematology | ||||||
| 06/30/2021 | F. Hoffmann-La Roche AG | HEMLIBRA (Biological) | — | In-kind items and services | $3,181.67 | Research |
| Study: A MULTICENTER, NON-INTERVENTIONAL STUDY EVALUATING BLEEDING INCIDENCE, HEALTH-RELATED QUALITY OF LIFE, AND SAFETY IN PATIENTS WITH HEMOPHILIA A UNDER STANDARD-OF-CARE TREATMENT • Category: Hematology | ||||||
| 06/30/2021 | F. Hoffmann-La Roche AG | HEMLIBRA (Biological) | — | In-kind items and services | $2,384.47 | Research |
| Study: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS, A MULTICENTER, OPEN-LABEL, PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB GIVEN EVERY 4 WEEKS Q4W IN PATIENTS WITH HEMOPHILIA A • Category: Hematology | ||||||
| 05/11/2021 | ABIOMED | Impella (Device) | Food and Beverage | In-kind items and services | $60.61 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/05/2021 | F. Hoffmann-La Roche AG | HEMLIBRA (Biological) | — | In-kind items and services | $540.23 | Research |
| Study: A MULTICENTER, NON-INTERVENTIONAL STUDY EVALUATING BLEEDING INCIDENCE, HEALTH-RELATED QUALITY OF LIFE, AND SAFETY IN PATIENTS WITH HEMOPHILIA A UNDER STANDARD-OF-CARE TREATMENT • Category: Hematology | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | HEMLIBRA (Biological) | — | In-kind items and services | $2,578.77 | Research |
| Study: A MULTICENTER, NON-INTERVENTIONAL STUDY EVALUATING BLEEDING INCIDENCE, HEALTH-RELATED QUALITY OF LIFE, AND SAFETY IN PATIENTS WITH HEMOPHILIA A UNDER STANDARD-OF-CARE TREATMENT • Category: Hematology | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | HEMLIBRA (Biological) | — | In-kind items and services | $344.96 | Research |
| Study: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITH INHIBITORS., A SINGLE-ARM, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ONCE WEEKLY SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS WITH INHIBITORS, A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRI • Category: Hematology | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $2,110.76 | Research |
| Study: Phase 3 Open Label Evaluating RO5534262 in Patients without Inhibitors, Phase 3 emicizumab Q4W in patients with hemophilia A, Phase III Inhibitor Study and Open Label Phase III Study of emicizumab in Hemophilia A Pediatrics Patients with Inhibitors • Category: Hematology | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $509.00 | Research |
| Study: Phase 3 Open Label Evaluating RO5534262 in Patients without Inhibitors, Phase 3 emicizumab Q4W in patients with hemophilia A, Phase III Inhibitor Study and Open Label Phase III Study of emicizumab in Hemophilia A Pediatrics Patients with Inhibitors • Category: Hematology | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $287.50 | Research |
| Study: Phase 3 Open Label Evaluating RO5534262 in Patients without Inhibitors, Phase 3 emicizumab Q4W in patients with hemophilia A, Phase III Inhibitor Study and Open Label Phase III Study of emicizumab in Hemophilia A Pediatrics Patients with Inhibitors • Category: Hematology | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $256.10 | Research |
| Study: Phase 3 Open Label Evaluating RO5534262 in Patients without Inhibitors, Phase 3 emicizumab Q4W in patients with hemophilia A, Phase III Inhibitor Study and Open Label Phase III Study of emicizumab in Hemophilia A Pediatrics Patients with Inhibitors • Category: Hematology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $6,160.00 | Research |
| Study: Emicizumab Pediatric Experience in Clinical Studies and Beyond • Category: Hematology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $5,160.31 | Research |
| Study: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITH INHIBITORS. • Category: Hematology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $4,353.83 | Research |
| Study: A MULTICENTER, NON-INTERVENTIONAL STUDY EVALUATING BLEEDING INCIDENCE, HEALTH-RELATED QUALITY OF LIFE, AND SAFETY IN PATIENTS WITH HEMOPHILIA A UNDER STANDARD-OF-CARE TREATMENT • Category: Hematology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $4,288.02 | Research |
| Study: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITH INHIBITORS. • Category: Hematology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $526.56 | Research |
| Study: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITH INHIBITORS., A SINGLE-ARM, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ONCE WEEKLY SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS WITH INHIBITORS, A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL • Category: Hematology | ||||||
| 09/30/2020 | F. Hoffmann-La Roche AG | Hemlibra (Biological) | — | In-kind items and services | $156.71 | Research |
| Study: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITH INHIBITORS., A SINGLE-ARM, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ONCE WEEKLY SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS WITH INHIBITORS, A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL • Category: Hematology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, NON-INTERVENTIONAL STUDY EVALUATING BLEEDING INCIDENCE, HEALTH-RELATED QUALITY OF LIFE, AND SAFETY IN PATIENTS WITH HEMOPHILIA A UNDER STANDARD-OF-CARE TREATMENT | F. Hoffmann-La Roche AG | $11,914 | 5 |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITH INHIBITORS. | F. Hoffmann-La Roche AG | $9,448 | 2 |
| Emicizumab Pediatric Experience in Clinical Studies and Beyond | F. Hoffmann-La Roche AG | $6,160 | 1 |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS | F. Hoffmann-La Roche AG | $3,895 | 1 |
| Phase 3 Open Label Evaluating RO5534262 in Patients without Inhibitors, Phase 3 emicizumab Q4W in patients with hemophilia A, Phase III Inhibitor Study and Open Label Phase III Study of emicizumab in Hemophilia A Pediatrics Patients with Inhibitors | F. Hoffmann-La Roche AG | $3,163 | 4 |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS, A MULTICENTER, OPEN-LABEL, PHASE III STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF EMICIZUMAB GIVEN EVERY 4 WEEKS Q4W IN PATIENTS WITH HEMOPHILIA A | F. Hoffmann-La Roche AG | $2,384 | 1 |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITH INHIBITORS., A SINGLE-ARM, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ONCE WEEKLY SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS WITH INHIBITORS, A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL | F. Hoffmann-La Roche AG | $683.27 | 2 |
| A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF PROPHYLACTIC EMICIZUMAB VERSUS NO PROPHYLAXIS IN HEMOPHILIA A PATIENTS WITH INHIBITORS., A SINGLE-ARM, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ONCE WEEKLY SUBCUTANEOUS ADMINISTRATION OF EMICIZUMAB IN HEMOPHILIA A PEDIATRIC PATIENTS WITH INHIBITORS, A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III CLINICAL TRI | F. Hoffmann-La Roche AG | $344.96 | 1 |
About Gallia Levy, MD, PHD
Gallia Levy, MD, PHD is a Hematology healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2008. The National Provider Identifier (NPI) number assigned to this provider is 1023271350.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Gallia Levy, MD, PHD has received a total of $38,054 in payments from pharmaceutical and medical device companies, with $5,154 received in 2022. These payments were reported across 18 transactions from 2 companies. The most common payment nature is "" ($37,993).
Ad
Practice Information
- Specialty Hematology
- Location San Francisco, CA
- Active Since 07/07/2008
- Last Updated 07/07/2008
- Taxonomy Code 207RH0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1023271350
Products in Payments
- Hemlibra (Biological) $23,809
- HEMLIBRA (Biological) $14,184
- Impella (Device) $60.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in San Francisco
Dr. Thomas Martin, Md, MD
Hematology — Payments: $128,592
Hematology $128,592
Karthik Ganapathi, Md, Phd, MD, PHD
Hematology — Payments: $27,997
Hematology $27,997
Dr. Katherine Matthay, M.d, M.D
Hematology — Payments: $14,481
Hematology $14,481
Dr. Scott Kogan, M.d, M.D
Hematology — Payments: $10,253
Hematology $10,253
Dr. Chuanyi Lu, M.d, M.D
Hematology — Payments: $7,309
Hematology $7,309
Alfred Chung
Hematology — Payments: $6,793
Hematology $6,793